Business, energy, technology, markets and global industry news from Business News Today

National Institutes of Health

PharmaDeviceNews National Institutes of Health
PleoPharma’s $6.5 million NIDA grant supports the Phase 3 CAN-004 trial of investigational PP-01 for cannabis withdrawal in adults with cannabis use disorder, putting the 420-patient study at the centre of the company’s late-stage development strategy. Representative image.
Pharma & Biotech

Can PP-01 become the first approved cannabis withdrawal treatment? PleoPharma’s Phase 3 test begins

PleoPharma secures $6.5M NIDA funding as a 420-patient Phase 3 trial tests PP-01 for cannabis withdrawal in adults with cannabis use disorder.

Read More
Greenstone Biosciences is advancing patient-derived cardiac cell research to identify potential therapies targeting cardiac fibrosis and cardiomyopathy in Duchenne muscular dystrophy following an NIH R61 grant. Representative image.
Pharma & Biotech

Can Greenstone Biosciences turn patient-derived heart cells into a Duchenne cardiomyopathy drug?

Greenstone Biosciences secured an NIH R61 grant to discover cardiac fibrosis drugs for Duchenne muscular dystrophy using iPSC and AI models.

Read More
Feinstein Institutes releases comprehensive human vagus nerve map to advance precision neuromodulation
Medical Devices & Diagnostics

How the Feinstein Institutes vagus nerve map may advance bioelectronic medicine

Feinstein Institutes releases a detailed human vagus nerve map that could sharpen neuromodulation design, but clinical validation remains essential.

Read More
Pharma & Biotech

How Sparian Biosciences’ Phase 1 launch of SBS-147 could reshape the non-opioid pain treatment landscape

Discover how Sparian Biosciences’ SBS-147 Phase 1 launch could change the race for safer non-opioid pain treatments. Read the full analysis.

Read More